Abstract

Contrast-induced acute kidney injury (CI-AKI) is a common clinical complication and an important cause of increased mortality, prolonged hospitalization, and increased medical costs. For taking effective interventions in CI-AKI, early diagnosis and active prevention are of key importance. Currently, early CI-AKI detection depends on serum creatinine (Scr) levels, which lags behind the actual time of renal injury and seriously affects early diagnosis and interventions. MicroRNA (miRNA) has been found to be a useful biomarker in early CI-AKI diagnosis. Several studies have reported on tissue and time-specific miRNAs in AKI as effective diagnostic biomarkers and potential therapeutic targets, but there are only a few studies on miRNA in CI-AKI. However, these studies are preliminary exploratory investigations on changes in miRNA expression in CI-AKI, and whether these specific miRNAs can be used as biomarkers for early CI-AKI diagnosis and as clinical therapeutic targets requires systematic and in-depth studies. Therefore, more sensitive and specific miRNAs of CI-AKI could be discovered, providing newer options and development directions for early diagnosis and intervention in clinical CI-AKI practice. This review evaluates the research progress on specific miRNAs in the early diagnosis of CI-AKI with an aim of providing basic data for the clinical application of these molecular markers in CI-AKI.

摘要

造影剂诱发的急性肾损伤（CI-AKI）是一种常见的临床并发症，也是导致死亡率增加、住院时间延长和医疗费用增加的重要原因。对于 CI-AKI 的有效干预，早期诊断和积极预防至关重要。目前，CI-AKI的早期检测依赖于血清肌酐（Scr）水平，滞后于肾损伤的实际发生时间，严重影响早期诊断和干预。已发现 MicroRNA (miRNA) 是早期 CI-AKI 诊断中有用的生物标志物。一些研究报道了 AKI 中的组织和时间特异性 miRNA 作为有效的诊断生物标志物和潜在的治疗靶点，但关于 CI-AKI 中 miRNA 的研究很少。然而，这些研究是对 CI-AKI 中 miRNA 表达变化的初步探索性研究，而这些特异性miRNA能否作为CI-AKI早期诊断的生物标志物和临床治疗靶点，还需要系统深入的研究。因此，可以发现更敏感和特异性的CI-AKI miRNA，为临床CI-AKI实践的早期诊断和干预提供新的选择和发展方向。本综述评价特异性miRNAs在CI-AKI早期诊断中的研究进展，旨在为这些分子标志物在CI-AKI中的临床应用提供基础数据。为临床 CI-AKI 实践中的早期诊断和干预提供更新的选择和发展方向。本综述评价特异性miRNAs在CI-AKI早期诊断中的研究进展，旨在为这些分子标志物在CI-AKI中的临床应用提供基础数据。为临床 CI-AKI 实践中的早期诊断和干预提供更新的选择和发展方向。本综述评价特异性miRNAs在CI-AKI早期诊断中的研究进展，旨在为这些分子标志物在CI-AKI中的临床应用提供基础数据。